Is NovoCure Ltd (NVCR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 16.7% / 30% | 30.2% / 30% | 9.3% / 30% | 1.96% / 5% | ✗ NOT HALAL |
| DJIM | 16.7% / 33% | 30.2% / 33% | 9.3% / 33% | 1.96% / 5% | ✓ HALAL |
| MSCI | 30.9% / 33% | 55.7% / 33% | 17.2% / 33% | 1.96% / 5% | ✗ NOT HALAL |
| S&P | 16.7% / 33% | 30.2% / 33% | 9.3% / 33% | 1.96% / 5% | ✓ HALAL |
| FTSE | 30.9% / 33% | 55.7% / 33% | 17.2% / 50% | 1.96% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 74.8% | |
| Operating Margin | -21.3% | |
| Net Margin | -20.8% | |
| Return on Equity (ROE) | -38.9% | |
| Return on Assets (ROA) | -9.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$49M |
| Free Cash Flow | -$76M |
| Total Debt | $248M |
| Debt-to-Equity | 72.9 |
| Current Ratio | 2.9 |
| Total Assets | $804M |
Price & Trading
| Last Close | $11.76 |
| 50-Day MA | $12.28 |
| 200-Day MA | $13.22 |
| Avg Volume | 1.9M |
| Beta | 0.7 |
|
52-Week Range
$9.82
| |
About NovoCure Ltd (NVCR)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NovoCure Ltd (NVCR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NovoCure Ltd is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NovoCure Ltd's debt ratio?
NovoCure Ltd's debt ratio is 16.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 30.9%.
What are NovoCure Ltd's key financial metrics?
NovoCure Ltd has a market capitalization of $1.2B, and revenue of $655M. The company maintains a gross margin of 74.8% and a net margin of -20.8%. Return on equity stands at -38.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.